CA2827446C - Ester derivatives of bimatoprost compositions and methods - Google Patents

Ester derivatives of bimatoprost compositions and methods Download PDF

Info

Publication number
CA2827446C
CA2827446C CA2827446A CA2827446A CA2827446C CA 2827446 C CA2827446 C CA 2827446C CA 2827446 A CA2827446 A CA 2827446A CA 2827446 A CA2827446 A CA 2827446A CA 2827446 C CA2827446 C CA 2827446C
Authority
CA
Canada
Prior art keywords
unsubstituted
substituted
alkyl
compound
bimatoprost
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2827446A
Other languages
English (en)
French (fr)
Other versions
CA2827446A1 (en
Inventor
David F. Woodward
Jenny W. Wang
Michael E. Garst
Robert M. Burk
Todd S. Gac
Neil J. Poloso
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CA2827446A1 publication Critical patent/CA2827446A1/en
Application granted granted Critical
Publication of CA2827446C publication Critical patent/CA2827446C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2827446A 2011-02-14 2012-02-13 Ester derivatives of bimatoprost compositions and methods Active CA2827446C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161442400P 2011-02-14 2011-02-14
US61/442,400 2011-02-14
PCT/US2012/024881 WO2012112451A1 (en) 2011-02-14 2012-02-13 Ester derivatives of bimatoprost compositions and methods

Publications (2)

Publication Number Publication Date
CA2827446A1 CA2827446A1 (en) 2012-08-23
CA2827446C true CA2827446C (en) 2020-06-23

Family

ID=45755562

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2827446A Active CA2827446C (en) 2011-02-14 2012-02-13 Ester derivatives of bimatoprost compositions and methods

Country Status (12)

Country Link
US (3) US8865766B2 (https=)
EP (1) EP2675786B1 (https=)
JP (1) JP5885271B2 (https=)
KR (1) KR101935068B1 (https=)
CN (1) CN103459368B (https=)
AR (1) AR088774A1 (https=)
AU (1) AU2012217922B2 (https=)
BR (1) BR112013020719B1 (https=)
CA (1) CA2827446C (https=)
RU (1) RU2599249C2 (https=)
TW (1) TWI642653B (https=)
WO (1) WO2012112451A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007111806A2 (en) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
DK2498783T3 (en) 2009-11-09 2018-12-10 Allergan Inc COMPOSITIONS AND PROCEDURES FOR STIMULATING HAIR GROWTH
EP3378480A1 (en) 2011-01-19 2018-09-26 Topokine Therapeutics, Inc. Methods and compositions for treating obesity
US8859616B2 (en) * 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
EP2912046A1 (en) * 2012-10-29 2015-09-02 Allergan, Inc. Phosphate esters of bimatoprost and the prostamides
WO2014081941A1 (en) 2012-11-21 2014-05-30 Topokine Therapeutics, Inc. Methods and compositions for locally increasing body fat
KR20150129733A (ko) * 2013-03-14 2015-11-20 알러간, 인코포레이티드 비마토프로스트를 포함하는 국소 조성물 및 이를 사용하여 모발 성장을 자극하는 방법
NO2753788T3 (https=) 2013-05-10 2018-06-16
WO2014186504A1 (en) 2013-05-15 2014-11-20 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
WO2015200425A1 (en) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Topical dosage regimen
US11478437B2 (en) 2016-07-05 2022-10-25 Jenivision Inc. Formulations for hair growth
JP7141025B1 (ja) * 2021-11-11 2022-09-22 エルデシエロ プライベート リミテッド 化合物、組成物、方法、及び製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5574066A (en) * 1992-10-28 1996-11-12 Allergan Intraocular pressure reducing 15-acyl prostaglandins
JP2818381B2 (ja) * 1994-01-18 1998-10-30 帝人株式会社 ７−チアプロスタグランジン類およびその製造法
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JPH10259179A (ja) * 1996-09-19 1998-09-29 Santen Pharmaceut Co Ltd 多置換アリールオキシ基を有するプロスタグランジン類およびその用途
US6395787B1 (en) * 2000-02-08 2002-05-28 Allergan Sales, Inc. Ocular hypotensive lipids
US7351404B2 (en) * 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
CA2850858A1 (en) 2005-09-16 2007-04-05 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
BRPI0807065A2 (pt) * 2007-01-31 2017-03-21 Allergan Inc biomateriais novos para liberação de fármaco ocular e um método para fazer e usar os mesmos
US7632867B2 (en) * 2007-10-31 2009-12-15 Meta Cosmetics, Llc Prostaglandin analog compositions to treat epithelial-related conditions
AR076731A1 (es) * 2008-05-09 2011-07-06 Pfizer Prostamidas donadoras de oxido nitrico, uso de los mismos y composiciones farmaceuticas
DK2498783T3 (en) 2009-11-09 2018-12-10 Allergan Inc COMPOSITIONS AND PROCEDURES FOR STIMULATING HAIR GROWTH

Also Published As

Publication number Publication date
WO2012112451A1 (en) 2012-08-23
BR112013020719B1 (pt) 2018-04-17
US20120295972A1 (en) 2012-11-22
TW201247613A (en) 2012-12-01
CA2827446A1 (en) 2012-08-23
EP2675786A1 (en) 2013-12-25
AU2012217922B2 (en) 2017-05-04
US20150005377A1 (en) 2015-01-01
CN103459368A (zh) 2013-12-18
TWI642653B (zh) 2018-12-01
BR112013020719A2 (pt) 2016-08-09
AU2012217922A1 (en) 2013-09-05
US20130324606A1 (en) 2013-12-05
US9499478B2 (en) 2016-11-22
KR20140015364A (ko) 2014-02-06
AR088774A1 (es) 2014-07-10
JP5885271B2 (ja) 2016-03-15
RU2013141849A (ru) 2015-03-27
JP2014513051A (ja) 2014-05-29
CN103459368B (zh) 2016-06-08
KR101935068B1 (ko) 2019-01-03
RU2599249C2 (ru) 2016-10-10
US8865766B2 (en) 2014-10-21
EP2675786B1 (en) 2018-12-26

Similar Documents

Publication Publication Date Title
CA2827446C (en) Ester derivatives of bimatoprost compositions and methods
JP7656589B2 (ja) エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体を用いて乳癌を治療する方法
AU2008203531B2 (en) Sulfonamides as potassium channel blockers
CA2882743C (en) Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
US12252471B2 (en) Isoquinoline compounds and their use in treating AhR imbalance
WO2014179263A1 (en) Therapeutic agents
CA2804797C (en) Therapeutic compositions for diabetic symmetrical polyneuropathy and/or tactile allodynia
KR20170010059A (ko) 치료적 화합물로서 신규한 ep4 작용제
US20150119367A1 (en) Phosphate Esters of Bimatoprost and the Prostamides
HK1191320A (en) Ester derivatives of bimatoprost compositions and methods
HK1191320B (en) Ester derivatives of bimatoprost compositions and methods
CA2939569A1 (en) Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
CA2962766A1 (en) Ester prodrugs of gamma-lactams and their use
AU2003259852A1 (en) Sulfonamides as potassium channel blockers

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170130

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20240814